---
title: "David Pauling Purchases 12,504 Shares of Sutro Biopharma (NASDAQ:STRO) Stock"
description: "David Pauling, an insider at Sutro Biopharma (NASDAQ:STRO), purchased 12,504 shares at $0.80 each on October 15, totaling $10,003.20. This acquisition increased his holdings to 71,737 shares, valued a"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/261600220.md"
published_at: "2025-10-17T10:18:26.000Z"
---

# David Pauling Purchases 12,504 Shares of Sutro Biopharma (NASDAQ:STRO) Stock

> David Pauling, an insider at Sutro Biopharma (NASDAQ:STRO), purchased 12,504 shares at $0.80 each on October 15, totaling $10,003.20. This acquisition increased his holdings to 71,737 shares, valued at $57,389.60, marking a 21.11% rise in his position. The transaction was disclosed to the SEC. Sutro Biopharma's stock opened at $0.88, with a market cap of $74.66 million and a PE ratio of -0.35. Analysts have mixed ratings on the stock, with an average target price of $4.47.

Sutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) insider David Pauling acquired 12,504 shares of Sutro Biopharma stock in a transaction on Wednesday, October 15th. The shares were purchased at an average price of $0.80 per share, with a total value of $10,003.20. Following the completion of the purchase, the insider owned 71,737 shares in the company, valued at $57,389.60. This represents a 21.11% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

## Sutro Biopharma Stock Performance

Shares of NASDAQ STRO opened at $0.88 on Friday. The firm's 50 day moving average price is $0.88 and its 200-day moving average price is $0.83. Sutro Biopharma, Inc. has a 52-week low of $0.52 and a 52-week high of $4.60. The company has a market cap of $74.66 million, a PE ratio of -0.35 and a beta of 1.61.

Sutro Biopharma (NASDAQ:STRO - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.14) EPS for the quarter, beating analysts' consensus estimates of ($0.39) by $0.25. Sutro Biopharma had a negative net margin of 201.32% and a negative return on equity of 852.70%. The firm had revenue of $63.74 million for the quarter, compared to analysts' expectations of $14.55 million. On average, analysts forecast that Sutro Biopharma, Inc. will post -2.92 earnings per share for the current fiscal year.

## Analyst Ratings Changes

* * *

* * *

A number of equities research analysts have recently commented on the stock. Wells Fargo & Company cut their price target on shares of Sutro Biopharma from $4.00 to $3.00 and set an "equal weight" rating on the stock in a report on Tuesday, August 12th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Sutro Biopharma in a report on Wednesday, October 8th. Finally, Wall Street Zen upgraded shares of Sutro Biopharma from a "sell" rating to a "hold" rating in a report on Saturday, September 13th. Two research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Sutro Biopharma has an average rating of "Hold" and an average target price of $4.47.

**Read Our Latest Stock Report on STRO**

## Institutional Trading of Sutro Biopharma

Institutional investors have recently made changes to their positions in the stock. Catalyst Funds Management Pty Ltd purchased a new stake in shares of Sutro Biopharma during the 2nd quarter valued at about $27,000. Cerity Partners LLC purchased a new stake in shares of Sutro Biopharma during the 1st quarter valued at about $25,000. Vontobel Holding Ltd. boosted its holdings in shares of Sutro Biopharma by 100.0% during the 1st quarter. Vontobel Holding Ltd. now owns 50,000 shares of the company's stock valued at $33,000 after acquiring an additional 25,000 shares during the last quarter. Savant Capital LLC purchased a new stake in shares of Sutro Biopharma during the 2nd quarter valued at about $37,000. Finally, CWM LLC boosted its holdings in shares of Sutro Biopharma by 73.2% during the 2nd quarter. CWM LLC now owns 56,657 shares of the company's stock valued at $40,000 after acquiring an additional 23,941 shares during the last quarter. Hedge funds and other institutional investors own 96.99% of the company's stock.

## Sutro Biopharma Company Profile

(Get Free Report)

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.

## Featured Articles

-   Five stocks we like better than Sutro Biopharma
-   How Technical Indicators Can Help You Find Oversold Stocks
-   Salesforce’s Long-Awaited Inflection is Here: Rally On!
-   Trading Halts Explained
-   Rocket Lab USA Receives Wall Street Validation: Time to Buy?
-   What is Short Interest? How to Use It
-   Archer Buys Rival's Patent Treasure Trove in Strategic Move

*This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to \[email protected\].*

Insider Buying or Selling at Sutro Biopharma?

Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Sutro Biopharma and related companies.

From Our Partners

INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off

Right now, we’re witnessing a monumental shift in the world.

Traders AgencyCapital Gains Tax Strategies for Seniors

Capital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...

SmartAsset$100 Trillion “AI Metal” Found in American Ghost Town

Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...

Brownstone ResearchBitcoin grabs headlines, but smart money likes this token

Bitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...

Crypto 101 MediaIf You Keep Cash In A U.S. Bank Account… Read This NOW

The Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...

Banyan Hill PublishingFront-Run Buffett's Shocking Gold Move

A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...

Golden Portfolio$15 Fund: Turn Gold Boom into Real Income

If you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...

Investors AlleyBuy UBER immediately

BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...

Chaikin Analytics

### Related Stocks

- [STRO.US - Sutro Biopharma](https://longbridge.com/en/quote/STRO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Sutro Biopharma 在最新的演示中重点介绍了其 ADC 平台 | Sutro Biopharma (STRO) 宣布了一项承销协议，计划以每股 13.98 美元的价格出售 787 万股，旨在筹集约 1.1 亿美元。这笔资金将使其资本资源增强至约 2.514 亿美元，延长其财务支撑至 2028 年第二季度， | [Link](https://longbridge.com/en/news/275525882.md) |
| 康斯托克资源｜10-K：2025 财年营收 22.2 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/276369088.md) |
| 就业数据强劲打击降息预期，美股基金遭遇三周以来首次资金净流出 | 强劲就业数据削弱降息预期，叠加 AI 颠覆担忧，导致美股基金遭遇三周来首次资金净流出（14.2 亿美元）。资金显著分化：大盘股失血 123.4 亿美元，小盘股逆势吸金 20.1 亿美元。避险下债券基金连续六周获流入，货币基金遭赎回。 | [Link](https://longbridge.com/en/news/275904573.md) |
| 意大利国家电力 (ADR) 以 400 万欧元购买了约 372,000 股自有股票 | 意大利国家电力 (ADR) 购买了 371,800 股自家股票，花费超过 350 万欧元，平均价格为每股 9.4901 欧元。这些交易发生在 2 月 9 日至 13 日之间，使公司的库藏股增至 1.36 亿股，占其股本的 1.3%。意大利国 | [Link](https://longbridge.com/en/news/276152722.md) |
| 美国汽油价格最高的地方在哪里？以下是 2026 年 2 月各州的平均价格 | 油价上涨了吗？随着日历进入三月，以下是各州普通无铅汽油每加仑的平均价格 | [Link](https://longbridge.com/en/news/276296283.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
